ENANTA PHARMACEUTICALS INC 8-K

What Happened

• On June 18, 2026, Enanta Pharmaceuticals, Inc. (ENTA) filed an Item 7.01 8-K (Regulation FD disclosure) to announce advancement of its zelicapavir clinical development program for respiratory syncytial virus (RSV).
• The company said it plans a registrational Phase 2b/3 clinical trial in high‑risk adults and a Phase 2b clinical trial in pediatric patients. Enanta furnished a press release (Exhibit 99.1) and a slide presentation titled “Zelicapavir Update” (Exhibit 99.2) with the filing.

Key Details

• Filing date: June 18, 2026 (8-K, Item 7.01 Regulation FD Disclosure).
• Planned trials: registrational Phase 2b/3 in high‑risk adults; Phase 2b in pediatric patients.
• Supporting materials: press release and presentation provided as Exhibits 99.1 and 99.2 to the 8-K.

Why It Matters

• Advancement to a registrational Phase 2b/3 trial is a material clinical development milestone: it defines the company’s next-step trial strategy and a pathway toward potential regulatory evaluation for zelicapavir in RSV.
• This filing is a program and development update (not an earnings or financial-reporting item). Investors should review the attached press release and presentation for details on timelines, trial design, and next milestones.